Veradermics (MANE) EPS (Basic) (2025 - 2026)
Veradermics (MANE) reported EPS (Basic) of -$1.32 for Q1 2026, up 93.33% on a YoY basis from -$0.68 in Q1 2025, and up 93.33% quarter-over-quarter from -$19.79 in Q1 2025.
Veradermics (MANE) EPS (Basic) (2025 - 2026) Analysis & Trends
Veradermics has reported EPS (Basic) for 2 years, with the latest figure at -$1.32 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Basic) rose 93.33% year-over-year to -$1.32; the trailing twelve-month figure through Mar 2026 stood at -$21.11 (changed N/A YoY), and the FY2025 full-year result was -$111.91, down 202.05% from the prior year.
- EPS (Basic) for Q1 2026 stood at -$1.32, up from -$19.79 in the prior quarter.
- The five-year high for EPS (Basic) was -$1.32 in Q1 2026, with the low at -$19.79 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 0.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.06 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.06 |
| 10 | Veradermics | 2.13 Bn | 2.13 Bn | - | -1.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.32 |
| Mar 31, 2025 | -19.79 |